Innovating With Purpose. Delivering With Precision.

Beanda is a pharmaceutical development company focused on selecting and advancing products that make commercial sense.

Execution capability matters, but the real value lies earlier — in choosing the right products to begin with. Programs are evaluated carefully, and only those with clear regulatory pathways, defensible IP, and realistic market potential move forward.

By uniting U.S. regulatory and IP leadership with India-based development and manufacturing, alongside Western commercial manufacturing across the EU and USA, Beanda delivers assets that partners can confidently evaluate, license, and launch.

Product development starts with selection, not formulation.

Each program follows a practical framework that brings together regulatory strategy, IP positioning, technical feasibility, manufacturing readiness, and market relevance from the outset. This approach reduces downstream surprises and increases the likelihood of successful commercialization.

Work includes 505(b)(2) development, niche and complex generics, first-to-file and Paragraph IV programs, formulation and analytical development, bioequivalence coordination, and dossier preparation — all aligned with requirements for USA and EU commercial manufacturing.

The pipeline is intentionally selective.

Every asset is chosen based on market need, competitive intensity, reimbursement logic, regulatory clarity, IP defensibility, technical complexity, and manufacturability. Programs advance only when these factors align.

The result is a focused set of assets that Beanda is confident presenting to in-licensing partners.

Pipeline details are shared under CDA.

Development activities are anchored in India, where a dedicated, long-term leased formulation development facility operates under direct U.S. regulatory and quality oversight.

This facility serves as the primary engine for formulation development, analytical and stability work, bioequivalence coordination, and regulatory documentation, offering speed and continuity without sacrificing compliance.

Where appropriate, additional development capabilities in Europe or other regions may be engaged based on program-specific or partner requirements.

Commercial manufacturing is supported through FDA-approved and EMA-approved CMOs in the United States and Europe.

This ensures assets are aligned with Western regulatory expectations and supported by reliable, inspectable supply chains. Providing a clear and compliant path to launch in regulated markets.

Assets are developed specifically to support efficient in-licensing and commercialization.

Partners may license products regionally or globally and receive complete technical and regulatory documentation, IP rationale, and access to compliant, scalable USA and EU manufacturing.

Commercial terms are structured to align incentives and typically include upfront fees, development or regulatory milestones, commercial supply agreements, and profit-sharing.